EichorEICHOR
Condition: Carcinoma Of Head And Or Neck Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Carcinoma Of Head And Or Neck

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
Phase 1 · 1 location(s) · Providence Health & Services · NCT04470024Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · Lumara Bio Oncologics GmbH · NCT05706129A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumor
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06469008A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Phase 1 · 8 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05194982A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Phase N/A · 1 location(s) · University of Colorado, Denver · NCT05517811A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcino
Phase 2 · 2 location(s) · Shanghai Henlius Biotech · NCT06857279First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Phase 2 · 2 location(s) · Jochen Lorch · NCT06959641Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcin
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06437522A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic So
Phase 1/Phase 2 · 120 location(s) · Daiichi Sankyo · NCT063300645-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Phase 2 · 1 location(s) · Barbara Burtness · NCT05317000Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06339619EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07617805Natural History Study of Children and Adults With Medullary Thyroid Cancer
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT01660984Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic
Phase 2 · 97 location(s) · AstraZeneca · NCT06535607Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancre
Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT05705492VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/Phase 2 · 15 location(s) · VM Oncology, LLC · NCT03556228Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
Phase 3 · 26 location(s) · UNICANCER · NCT04747054Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Phase 1 · 1 location(s) · Therorna · NCT07081984Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 · 2 location(s) · Emory University · NCT06636734A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 12 location(s) · Pliant Therapeutics, Inc. · NCT06270706A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carc
Phase 3 · 35 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06860971TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Portage Biotech · NCT04969315Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06935188Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cyc
Phase 3 · 1 location(s) · Fudan University · NCT05772208A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC
Phase 2 · 2 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT04992559
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.